References
Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34:1199–1204
Chan JA, Zhang H, Roberts PS et al (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236–1242
Hoshino T, Wilson BC, Ellis WG (1975) Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropathol Exp Neurol 34:263–281
Kros JM, Schouten WC, Janssen PJ, van der Kwast TH (1996) Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study. Acta Neuropathol 91:99–103
Krouwer HG, Davis RL, Silver P, Prados M (1991) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:399–406
Lin YX, Lin K, Kang DZ et al (2015) Similar PDK1-AKT-mTOR pathway activation in balloon cells and dysmorphic neurons of type II focal cortical dysplasia with refractory epilepsy. Epilepsy Res 112:137–149
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820
Mirzaa GM, Parry DA, Fry AE et al (2014) De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Nat Genet 46:510–515
Ohta T, Kim YH, Oh JE et al (2014) Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. J Neuropathol Exp Neurol 73:908–915
Okamoto Y, Di Patre PL, Burkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56
Peraud A, Ansari H, Bise K, Reulen HJ (1998) Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien) 140:1213–1222
Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res Off J Am Assoc Cancer Res 8:1117–1124
Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D et al (2016) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 131(6):903–910
Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437
Walker AJ, Wedam S, Amiri-Kordestani L et al (2016) FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 22:4968–4972
Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H (1998) p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 95:559–564
Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76:277–284
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sahm, F., Korshunov, A., Schrimpf, D. et al. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathol 133, 325–327 (2017). https://doi.org/10.1007/s00401-016-1657-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-016-1657-7